Medivation Gets $110M Upfront From Astellas In Prostate Cancer Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
As in its Dimebon collaboration with Pfizer, the biotech gets significant U.S. profit-sharing along with an option for co-promotion.
You may also be interested in...
With Muted Expectations For Provenge, Dendreon Restructures, Cuts Staff
A quarter of its employees, including the COO and many in manufacturing and administrative positions, will be dismissed.
With Muted Expectations For Provenge, Dendreon Restructures, Cuts Staff
A quarter of its employees, including the COO and many in manufacturing and administrative positions, will be dismissed.
Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib
In a worldwide deal excluding Asia, the two companies will split both revenues and development costs 50/50 in North America and Europe.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: